Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model
Secli et al, Nous-PEV neoadjuvant, JITC Nov 2025
Secli et al, Nous-PEV neoadjuvant, JITC Nov 2025
New data from Phase 1b/2 trial show annual NOUS-209 retreatment boosts durable T cell immunity in Lynch Syndrome (LS) carriers. First clinical evidence of NOUS-209 cancer interception approach [...]
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.